Published in

Wiley, Pigment Cell & Melanoma Research, 3(34), p. 629-640, 2020

DOI: 10.1111/pcmr.12944

Links

Tools

Export citation

Search in Google Scholar

The impact of BRAF mutation status on clinical outcomes with anti‐PD‐1 monotherapy versus combination ipilimumab/nivolumab in treatment‐naïve advanced stage melanoma

Journal article published in 2020 by Vincent T. Ma ORCID, Stephanie Daignault‐Newton, Jessica J. Waninger, Sara Journey, Zoey Chopra, Alangoya Tezel, Bruce G. Redman, Leslie A. Fecher, Michael D. Green, Ajjai S. Alva, Christopher D. Lao
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO